三阴性乳腺癌（TNBC）作为一种侵袭性肿瘤，提出了临床挑战，与不良预后相关。肿瘤浸润淋巴细胞（TIL）作为潜在的预后生物标志物引起了人们的兴趣。然而，不同 TIL 率之间的结果差异仍未得到充分探讨。我们检索了 PubMed、Scopus、Web of Science 和 Cochrane 数据库，以查找有关 TIL 对接受新辅助化疗的 TNBC 患者预后价值的研究。计算二元终点的风险比 (HR) 或优势比 (OR)，置信区间 (CI) 为 95%。纳入了 29 项研究，涉及 6161 名受试者 (80.41%)， TNBC。 TIL 截止值范围为 10% 至 60%，其中 50% 是最相关的值。与TIL低表达组相比，无病生存期（DFS）（HR 0.71；95% CI 0.61-0.82；p < 0.00001）和总生存期（OS）（HR 0.76；95% CI 0.63-0.90；p = 0.002) 率随着 TIL 浸润的增加而显着改善。在淋巴细胞亚型 CD4   和 CD8   的亚组分析中，两种亚型的 TIL 率均较高，具有统计学意义，每种亚型均与 DFS（HR 0.48；95% CI 0.33-0.71；p = 0.0002）和 OS（HR 0.53；95% CI 0.33-0.71；p = 0.0002）和 OS 的改善相关。 95% CI 0.36-0.78；p = 0.001），无论主要浸润的是哪种细胞亚型。完整的病理反应分析显示，较高 TIL 组的 TIL（OR 1.29；95% CI 1.13-1.48；p = 0.0003）和 Ki-67（OR 2.74；95% CI 2.01-3.73；p = 0.0003）的比率优于对照组。 p< 0.00001) 分析。TNBC 患者中较高的 TIL 表达与显着改善的 DFS、OS 和 pCR 结果相关。© 2024。作者获得 Federación de Sociedades Españolas de Oncología (FESEO) 的独家许可。

Triple-negative breast cancer (TNBC) presents a clinical challenge as an aggressive tumor, correlated with unfavorable prognosis. Tumor-infiltrating lymphocytes (TILs) have garnered interest as a potential prognostic biomarker. However, the disparity in outcomes between varying TILs rates remains inadequately explored.PubMed, Scopus, Web of Science, and Cochrane databases were searched for studies about the prognostic value of TILs in patients with TNBC receiving neoadjuvant chemotherapy. The hazard ratios (HRs) or odds ratios (ORs) were computed for binary endpoints, with 95% confidence intervals (CIs).Twenty-nine studies were included, involving a population of six thousand one hundred sixty-one (80.41%) with TNBC. The cut-off TILs value ranged from 10 to 60%, with 50% being the most related value. Compared with the low-TIL expression group, the disease-free survival (DFS) (HR 0.71; 95% CI 0.61-0.82; p < 0.00001) and overall survival (OS) (HR 0.76; 95% CI 0.63-0.90; p = 0.002) rates showed significant improvement with higher TIL infiltrations. In the subgroup analyses of the lymphocyte subtypes CD4 + and CD8 + , there was statistical significance favoring higher TILs rates in both subtypes, each associated with improved DFS (HR 0.48; 95% CI 0.33-0.71; p = 0.0002) and OS (HR 0.53; 95% CI 0.36-0.78; p = 0.001), regardless of which cell subtype was predominantly infiltrated. The complete pathological response analysis showed better rates for the higher TIL group than the control for both the TIL (OR 1.29; 95% CI 1.13-1.48; p = 0.0003) and Ki-67 (OR 2.74; 95% CI 2.01-3.73; p < 0.00001) analyses.Higher expressions of TILs in patients with TNBC were associated with improved significantly DFS, OS, and pCR outcomes.© 2024. The Author(s), under exclusive licence to Federación de Sociedades Españolas de Oncología (FESEO).